Abstract
Generally, the new strategy in cancer drug discovery and development is to define and validate the most promising cancer related molecular targets to which new drugs can be designed. For small molecule drugs, the focus is on interfering with molecular targets that contribute to deregulated cell growth and signaling pathways, predominantly within the cancer cell. Antigens aberrantly expressed on the cancer cell surface also afford possible valid molecular targets. Thus antibodies against tumor related antigens are a class of drugs that fit the new paradigm for cancer drug development and treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Köhler, G., Milstein, C. Continuous culture of fused cells secreting antibody of predefined specifity, Nature. 256: 495–497, 1975.
Gavilondo, J. V., Larrick, J. W. Antibody engineering at the millennium, Biotechniques. 29: 128–145, 2000.
Caprara, M.,Nilsen, T. RNA: versatility in form and function, Nature Structural Biology. 7: 831–833, 2000.
Schein, C. H. From housekeeper to microsurgeon: The diagnostic and therapeutic potential of ribonucleases, Nature Biotechnol. 15: 529–536, 1997.
Rybak, S. M., Newton, D. L. Natural and engineered cytotoxic ribonucleases: Therapeutic Potential, Exp. Cell Res. 253: 325–335, 1999.
Leland, P. A. and Raines, R. T. Cancer Chemotherapy–ribonucleases to the rescue, Chem. Biol. 8: 405–413, 2001.
Mikulski, S. M., Grossman, A. M., Carter, P. W., Shogen, K., Costanzi, J. J. Phase 1 human clinical trial of ONCONASE (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors, Int. J. Oncol. 3: 57–64, 1993.
Iordanov, M. S., Ryabinina, O. P., Wong, J., Dinh, T.-H., Newton, D. L., Rybak, S. M., Magun, B. E. Molecular determinants of programmed cell death induced by the cytotoxic ribonuclease onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis, Cancer Res. 60: 1983–1994, 2000.
Iordanov, M., Wong, J., Newton, D., Rybak, S., Bright, R., Flavell, R., davis, R., Magun, B. Differential requirement for the stress-activated protein kinase/c-Jun NH2terminal kinase in RNA damage-induced apoptosis in primary and in immortalized fibroblasts, Molec Cell Biol Res Corn. 4: 122–128, 2000.
D’Alessio, G. New and cryptic biological messages from RNases, Trends in Cell Biol. 3: 106–109, 1993.
Cinatl, J. J., Cinatl, J., Kotchetkov, R., Motousek, J., Woodcock, B., Koehl, U., Vogel, J., Kornhuber, H., Schwabe, D. Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs, Anticancer res. 20: 853–859, 2000.
Sakakibara, R., Hashida, K., Tominaga, N., Sakai, K., Ishiguro, M., Imamura, S., Ohmatsu, F.,Sato, E. A putative mouse oocyte maturation inhibitory protein from urine of pregnant women: N-terminal sequence homology with human nonsecretory ribonuclease, Chem. Pharm. Bull. 39: 146–149, 1991.
Newton, D. L., Rybak, S. M. Unique recombinant human ribonuclease and inhibition of kaposi’s sarcoma cell growth, J Natl. Cancer Inst. 90: 1787–1791, 1998.
Better, M., Chang, C. P., Robinson, R. R., Horwitz, A. H. Escherichia coli secretion of an active chimeric antibody fragment, Science. 240: 1041–3., 1988.
Skerra, A., Pluckthun, A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli, Science. 240: 1038–41., 1988.
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., Crea, R.,, Oppermann, H. Protein engineering of antibody binding sites: recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli, Proc Natl Acad Sci U S A. 85: 5879–5883, 1988.
Glockshuber, R., Malia, M., Pfitzinger, I., Pluckthun, A. A comparison of strategies to stabilize immunoglobulin Fv fragments, Biochemistry. 29: 1362–1367, 1990.
Adams, G. P., McCartney, J. E., Tai, M. S., Oppermann, H., Huston, J. S., Stafford, W. F. d., Bookman, M. A., Fand, I., Houston, L. L., Weiner, L. M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-cerbB-2 single-chain Fv, Cancer Res. 53: 4026–4034, 1993.
Holliger, P., Prospero, T., Winter, G. “Diabodies”: small bivalent and bispecific antibody fragments, Proc Natl Acad Sci U S A. 90.• 6444–8., 1993.
Kortt, A. A., Lah, M., Oddie, G. W., Gruen, C. L., Burns, J. E., Pearce, L. A., Atwell, J. L., McCoy, A. J., Howlett, G. J., Metzger, D. W., Webster, R. G., Hudson, P. J. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five-and ten-residue linkers form dimers and with zero-residue linker a trimer, Protein Eng. 10: 423–33., 1997.
Rybak, S. M.,Newton, D. L. Immunoenzymes. In: S. M. Chamow and A. Ashkenazi (eds.), Antibody Fusion Proteins, pp. 53–110. New York, NY: John Wiley and Sons, 1999.
Newton, D. L., Hansen, H. J., Mikulski, S. M., Goldenberg, D. M., Rybak, S. M. Potent and specific antitumor activity of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma, Blood. 97: 528535, 2001.
Hursey, M., Newton, D. L., Hansen, H., Ruby, D., Goldenberg, D. M., Rybak, S. M. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics, Leukemia and Lymphoma 1–7, 2001.
Baluna, R. and Vitetta, E. S. Vascular leak syndrome: a side effect of immunotherapy, Immunopharmacol. 37.• 117–132, 1997.
Newton, D. L., Rybak, S. M. Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA, Expert Opin Biol Ther. 1: 995–1003, 2001.
Adams, G. P., Schier, R., McCall, A. M., Crawford, R. S., Wolf, E. J., Weiner, L. M., Marks, J. D. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu, Br J Cancer. 77: 1405–12, 1998.
Milenic, D. E., Yokota, T., Filpula, D. R., Finkelman, M. A., Dodd, S. W., Wood, J. F., Whitlow, M., Snoy, P., Schlom, J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49, Cancer Res. 51: 6363–71, 1991.
Berinstein, N. L., Grillo-Lopez, A. J., White, C. A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P., Shen, D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non- Hodgkin’s lymphoma, Ann Oncol. 9: 995–1001., 1998.
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol. 17: 2639–48., 1999.
Clauss, M. A., Jain, R. K. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues, Cancer Res. 50: 3487–92, 1990.
Adams, G. P., Schier, R., McCall, A., Wolf, E. J., Marks, J. D., Weiner, L. M. Tumor targeting properties of anti-c-erb-2 single-chain Fv molecules over a wide range of affinities for the same epitope, Tumor Targeting. 2: 154, 1996.
Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., Weiner, L. M. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies, Cancer Res. 58: 485–90, 1998.
Weinstein, J. N., Eger, R. R., Covell, D. G., Black, C. D., Mulshine, J., Carrasquillo, J. A., Larson, S. M., Keenan, A. M. The pharmacology of monoclonal antibodies, Ann N Y Acad Sci. 507: 199–210, 1987.
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., Weiner, L. M. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules, Cancer Res. 61: 4750–5., 2001.
Nielsen, U. B., Adams, G. P., Weiner, L. M., Marks, J. D. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity [In Process Citation], Cancer Res. 60: 6434–40, 2000.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rybak, S.M., Arndt, M., Krauss, J., Newton, D.L., Vu, B.K., Zhu, Z. (2002). Targeted Apoptosis: Antibodies Linked to RNA Damaging Agents. In: Muzykantov, V., Torchilin, V. (eds) Biomedical Aspects of Drug Targeting. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-4627-3_14
Download citation
DOI: https://doi.org/10.1007/978-1-4757-4627-3_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5312-4
Online ISBN: 978-1-4757-4627-3
eBook Packages: Springer Book Archive